Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Agilon Health (AGL) EBIT: 2019-2024

Historic EBIT for Agilon Health (AGL) over the last 6 years, with FY2024 value amounting to -$292.1 million.

  • Agilon Health's EBIT rose 167.33% to -$131.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$377.5 million, marking a year-over-year decrease of 837.77%. This contributed to the annual value of -$292.1 million for FY2024, which is 2584.6% down from last year.
  • Per Agilon Health's latest filing, its EBIT stood at -$292.1 million for FY2024, which was down 2584.6% from -$232.1 million recorded in FY2023.
  • In the past 5 years, Agilon Health's EBIT ranged from a high of -$56.7 million in FY2020 and a low of -$372.2 million during FY2021
  • For the 5-year period, Agilon Health's EBIT averaged around -$211.7 million, with its median value being -$232.1 million (2023).
  • As far as peak fluctuations go, Agilon Health's EBIT plummeted by 55682.42% in 2021, and later skyrocketed by 7169.1% in 2022.
  • Agilon Health's EBIT (Annual) stood at -$56.7 million in 2020, then plummeted by 556.82% to -$372.2 million in 2021, then soared by 71.69% to -$105.4 million in 2022, then plummeted by 120.29% to -$232.1 million in 2023, then dropped by 25.85% to -$292.1 million in 2024.
  • Its EBIT stands at -$292.1 million for FY2024, versus -$232.1 million for FY2023 and -$105.4 million for FY2022.